CSO Jan Stenvang will pitch the background and status of Scandion Oncology A/S. Emphasis will be on the main drug SCO-101, which is ready for Phase II studies, and that Scandion Oncology plans an IPO in the fall of 2018.
The MVA Oncology Network meeting is an investor pitch evening bringing together life science investors and actors within oncology. See the program here: http://mva.org/event/mva-oncology-network-meeting-6/